GlassScriptPhysician profile
Erica Flores
NPI 1851685309
$11,601.09
in general payments reported to CMS, 2019-2025
39 companies · $313 in 2025
The $313 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $505 · 2020: $426 · 2021: $854 · 2022: $784 · 2023: $6,945 · 2024: $1,775 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,039 · Consulting Fee: $3,200 · Travel and Lodging: $1,794.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,039.01 |
| Consulting Fee | $3,200.00 |
| Travel and Lodging | $1,794.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $6,614.87 | 2019-2025 | Cardiomems, Mitraclip, Jot Dx |
| Novartis Pharmaceuticals Corporation | $507.85 | 2019-2025 | |
| Heartflow, INC. | $455.89 | 2023-2024 | Ffrct |
| Boston Scientific Corporation | $343.04 | 2019-2024 | Watchman Flx, Watchman Access System |
| Kestra Medical Technology Services, INC. | $330.70 | 2023-2025 | Assure Wcd |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $280.26 | 2019-2025 | Lifevest |
| Bardy Diagnostics, INC. | $270.00 | 2019-2022 | |
| Novo Nordisk INC | $232.01 | 2021-2024 | Ozempic |
| Sanofi-Aventis U.S. LLC | $231.21 | 2019-2023 | |
| Atricure, INC. | $194.24 | 2023-2024 | |
| Pfizer INC. | $191.90 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $188.49 | 2021-2024 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $184.03 | 2019-2025 | Eliquis, Camzyos |
| Amgen INC. | $165.69 | 2020-2025 | Repatha, Repatha |
| Tactile Systems Technology INC | $158.60 | 2019-2025 | Flexitouch Plus, Entre Plus, Nimbl |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $126.08 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $111.70 | 2021-2023 | Verquvo |
| Edwards Lifesciences Corporation | $107.91 | 2020-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Janssen Pharmaceuticals, INC | $102.47 | 2019-2023 | Xarelto |
| Baxter Healthcare | $91.96 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Medtronic, INC. | $91.79 | 2021-2023 | Corevalve Evolut R |
| Medtronic Vascular, INC. | $67.12 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $58.04 | 2019-2020 | |
| Astellas Pharma US INC | $57.69 | 2019-2021 | |
| Lexicon Pharmaceuticals, INC. | $39.86 | 2024 | |
| Cvrx, INC. | $38.20 | 2024 | Barostim Neo System |
| Alnylam Pharmaceuticals INC. | $37.82 | 2023-2025 | Amvuttra |
| Esperion Therapeutics, INC. | $36.73 | 2021-2022 | |
| Scpharmaceuticals INC. | $35.79 | 2023-2025 | |
| Ge Healthcare | $35.06 | 2023 | |
| Impulse Dynamics (USA) INC. | $32.18 | 2022 | |
| Cleerly, INC. | $30.30 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Philips North America LLC | $30.15 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $25.49 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $25.05 | 2024 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $23.68 | 2023 | Evkeeza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.74 | 2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $15.39 | 2023 | |
| Acacia Pharma INC | $15.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erica Flores listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.